Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FoldRx Pharmaceuticals

Latest From FoldRx Pharmaceuticals

Deal Watch: Takeda Signs Broad Cancer Collaboration With Nektar

Takeda will pair five cancer candidates with different mechanisms of action with Nektar's NKTR-214 and Merck follows up its Phase III disappointment verubecestat by licensing a preclinical Alzheimer's drug from Teijin.

Deals M & A

F-Prime Plays The Long Game In Health Care Investing

With strong backing, F-Prime Capital Partners can make large, high-risk bets around the world — and keep doubling down. An interview with F-Prime Managing Partner Stephen Knight.


Orphans Should Live Alone

For larger organizations with interests in rare diseases, Bionest Partners believes it is necessary to maintain a separation from the rest of the company in order to keep the culture needed for successful product commercialization. Easier said than done.

BioPharmaceutical Strategy

Dimension Expands Board

Dimension Therapeutics, Inc., a company developing liver-directed treatments for diverse genetic disorders, has elected of Dr Georges Gemayel, former executive vice-president of Genzyme Corporation and Arlene M. Morris, former CEO of Syndax Pharmaceuticals, to its board of directors. Dimension has also announced that Donald J. Hayden, Jr. is leaving his position as a member of the board. Previously, Gemayel was executive chair of Vascular Magnetics Inc., Syndexa, and FoldRx Pharmaceuticals, Inc (acquired by Pfizer). And Morris was previously president and CEO of Affymax, Inc.

See All

Company Information